1.Validating lactate dehydrogenase (LDH) as a component of the PLASMIC predictive tool (PLASMIC-LDH)
Christopher Chin KEONG LIAM ; Jim Yu-Hsiang TIAO ; Yee Yee YAP ; Yi Lin LEE ; Jameela SATHAR ; Simon MCRAE ; Amanda DAVIS ; Jennifer CURNOW ; Robert BIRD ; Philip CHOI ; Pantep ANGCHAISUKSIRI ; Sim Leng TIEN ; Joyce Ching MEI LAM ; Doyeun OH ; Jin Seok KIM ; Sung-Soo YOON ; Raymond Siu-Ming WONG ; Carolyn LAUREN ; Eileen Grace MERRIMAN ; Anoop ENJETI ; Mark SMITH ; Ross Ian BAKER
Blood Research 2023;58(1):36-41
Background:
The PLASMIC score is a convenient tool for predicting ADAMTS13 activity of <10%.Lactate dehydrogenase (LDH) is widely used as a marker of haemolysis in thrombotic thrombocytopenic purpura (TTP) monitoring, and could be used as a replacement marker for lysis. We aimed to validate the PLASMIC score in a multi-centre Asia Pacific region, and to explore whether LDH could be used as a replacement marker for lysis.
Methods:
Records of patients with thrombotic microangiopathy (TMA) were reviewed. Patients’ ADAMTS13 activity levels were obtained, along with clinical/laboratory findings relevant to the PLASMIC score. Both PLASMIC scores and PLASMIC-LDH scores, in which LDH replaced traditional lysis markers, were calculated. We generated a receiver operator characteristics (ROC) curve and compared the area under the curve values (AUC) to determine the predictive ability of each score.
Results:
46 patients fulfilled the inclusion criteria, of which 34 had ADAMTS13 activity levels of <10%. When the patients were divided into intermediate-to-high risk (scores 5‒7) and low risk (scores 0‒4), the PLASMIC score showed a sensitivity of 97.1% and specificity of 58.3%, with a positive predictive value (PPV) of 86.8% and negative predictive value (NPV) of 87.5%. The PLASMIC-LDH score had a sensitivity of 97.1% and specificity of 33.3%, with a PPV of 80.5% and NPV of 80.0%.
Conclusion
Our study validated the utility of the PLASMIC score, and demonstrated PLASMIC-LDH as a reasonable alternative in the absence of traditional lysis markers, to help identify high-risk patients for treatment via plasma exchange.
2.Improving prescribing for older patients - 'Yes S-I-R-E!'
Ting Ting Selina CHEONG ; Sharifah Munirah ALHAMID ; Fu Yin LI ; Swee Tee Wendy ANG ; Kim Hwa Jim LIM
Singapore medical journal 2019;60(6):298-302
INTRODUCTION:
Polypharmacy and inappropriate prescribing are associated with negative health outcomes in the elderly. Several prescribing tools have been developed to assess medication appropriateness. Explicit (criteria-based) tools often do not take into account patients' preferences and comorbidities, and have little room for individualised clinical judgement.
METHODS:
A cross-sectional observational study was conducted in 243 elderly patients admitted to the Geriatric Medicine service in a Singapore tertiary hospital over one month. We incorporated an implicit (judgement-based) tool developed by Scott et al into a mnemonic, 'S-I-R-E', to assess medication appropriateness: S = symptoms ('Have symptoms resolved?'), I = indication ('Is there a valid indication?'), R = risks ('Do risks outweigh benefits?') and E = end of life ('Is there short life expectancy limiting clinical benefit?').
RESULTS:
Inappropriate prescribing was present in 27.6% of patients. The most common reason for inappropriateness of medications was lack of valid indication (62.2%), followed by high risk-benefit ratio (20.7%). The most common medications that lacked valid indication were supplements and proton pump inhibitors. Polypharmacy was found in 93% of patients and was significantly associated with inappropriate prescribing (p = 0.047).
CONCLUSION
Inappropriate prescribing and polpharmacy are highly prevalent in the hospitalised elderly. The 'S-I-R-E' mnemonic can be used as a memory aid and practical framework to guide appropriate prescribing in the elderly.
3.Differences in attitudes to end-of-life care among patients, relatives and healthcare professionals.
Guat Cheng ANG ; Di ZHANG ; Kim Hwa Jim LIM
Singapore medical journal 2016;57(1):22-28
INTRODUCTIONThis study explored and compared the differences in attitudes toward end-of-life care among patients, relatives and healthcare professionals, including doctors and nurses.
METHODSWe performed a descriptive study on a cross-section of the population of a tertiary hospital in Singapore. Data was collected using a questionnaire survey involving 50 participants from each of the four groups of patients, relatives, doctors and nurses.
RESULTSFamily members were the most commonly nominated surrogate decision-makers by the patient group (76%) and the majority of the relative group (74%) felt comfortable deciding on end-of-life care for their loved ones. However, the patient and relative groups differed significantly in their preferences on end-of-life care options, including cardiopulmonary resuscitation (CPR) (p = 0.001), intubation (p = 0.003), nasogastric tube feeding (p < 0.001) and the use of antibiotics (p = 0.023). Doctors, nurses and relatives demonstrated differences in preference between end-of-life care for themselves and for their loved ones, especially with regard to the use of nasogastric tube feeding. There was also a difference between patients and doctors in their decisions on CPR (p < 0.001) and intubation (p = 0.008).
CONCLUSIONThis study demonstrated the importance of early planning for end-of-life care. This must be initiated proactively by healthcare professionals to engage patients in a culturally sensitive manner to discuss their preferences, in order to facilitate open communication between the patient and family.
Adult ; Aged ; Aged, 80 and over ; Attitude of Health Personnel ; Attitude to Health ; Cardiopulmonary Resuscitation ; psychology ; Cross-Sectional Studies ; Decision Making ; Family ; psychology ; Female ; Health Personnel ; psychology ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Surveys and Questionnaires ; Terminal Care ; psychology ; Young Adult
4.Diagnosis and Treatment for Deep Nontuberculous Mycobacteria Infection of the Hand and Wrist.
Ho Youn PARK ; Jun O YOON ; Jin Woong PARK ; Jaeyoun YOON ; Jim Sam KIM
Journal of the Korean Society for Surgery of the Hand 2015;20(3):119-126
PURPOSE: The purpose of this study was to present a systematic treatment method for nontuberculous mycobacteria (NTM) infection of the hand and wrist to gain better clinical outcomes. METHODS: 10 patients of deep NTM infection of the hand and wrist were reviewed. Extensive debridement was performed in all cases. When biopsy result suggested mycobacterial infection such as granulomatous inflammation, empirical tuberculosis medication was started. After culture confirmed NTM growth, the species was identified and in vitro sensitivity test was performed. Then medication was switched according to the results. Functional outcomes of the hand and wrist were measured by total active motion of the fingers and by range of motion of the wrist respectively. RESULTS: Diagnosis was tenosynovitis in seven patients, infective arthritis and osteomyelitis combined with tenosynovitis of the wrist in three patients. Two patients had recurred skin ulcer during follow-up period and undergone second debridement. After second operation, no patient had a persistent discharging sinus and all patient were completely healed during follow-up period. Functional outcome of the eight patients who had NTM infection of their hand was excellent in two, good in four, fair in one, poor in one. Mean range of motion of the two patients who had osteomyelitis of their wrist was dorsiflexion 20degrees, volar flexion 15degrees, radial deviation 0degrees, ulnar deviation 15degrees. CONCLUSION: Our standardized treatment protocol can be helpful for treatment of deep NTM infection of the hand and wrist.
Arthritis
;
Biopsy
;
Clinical Protocols
;
Debridement
;
Diagnosis*
;
Fingers
;
Follow-Up Studies
;
Hand*
;
Humans
;
Inflammation
;
Nontuberculous Mycobacteria*
;
Osteomyelitis
;
Range of Motion, Articular
;
Skin Ulcer
;
Tenosynovitis
;
Tuberculosis
;
Wrist*
5.Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor.
Jung Sun CHO ; Sung Ho HER ; Ju Yeal BAEK ; Mahn Won PARK ; Hyoung Doo KIM ; Myung Ho JEONG ; Young keun AHN ; Shung Chull CHAE ; Seung Ho HUR ; Taek Jong HONG ; Young Jo KIM ; In Whan SEONG ; Jei Keon CHAE ; Jay Young RHEW ; In Ho CHAE ; Myeong Chan CHO ; Jang Ho BAE ; Seung Woon RHA ; Chong Jim KIM ; Donghoon CHOI ; Yang Soo JANG ; Junghan YOON ; Wook Sung CHUNG ; Jeong Gwan CHO ; Ki Bae SEUNG ; Seung Jung PARK
Journal of Korean Medical Science 2010;25(11):1601-1608
The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in the Korean Acute Myocardial Infarction Registry (KAMIR) were assigned to either of two groups: a group with Gp IIb/IIIa inhibitor (n=476) or a group without Gp IIb/IIIa inhibitor (n=2,059). These groups were further subdivided according to the use of LMWH with low dose UFH (n=219) or UFH alone (n=257). The primary end points were cardiac death or myocardial infarction during the 30 days after the registration. The primary end point occurred in 4.1% (9/219) of patients managed with LMWH during PCI and Gp IIb/IIIa inhibitor and 10.8% (28/257) of patients managed with UFH and Gp IIb/IIIa inhibitor (odds ratio [OR], 0.290; 95% confidence interval [CI], 0.132-0.634; P=0.006). Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). For patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more beneficial than UFH.
Acute Disease
;
Aged
;
Drug Therapy, Combination
;
Female
;
Hemorrhage
;
Heparin/*therapeutic use
;
Heparin, Low-Molecular-Weight/*therapeutic use
;
Humans
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Myocardial Infarction/epidemiology/mortality/*therapy
;
Myocardial Revascularization
;
Odds Ratio
;
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors/metabolism
;
Prognosis
;
Registries
6.Comparison of Clinical Outcomes Following Acute Myocardial Infarctions in Hypertensive Patients With or Without Diabetes.
Min Goo LEE ; Myung Ho JEONG ; Youngkeun AHN ; Shung Chull CHAE ; Seung Ho HUR ; Taek Jong HONG ; Young Jo KIM ; In Whan SEONG ; Jei Keon CHAE ; Jay Young RHEW ; In Ho CHAE ; Myeong Chan CHO ; Jang Ho BAE ; Seung Woon RHA ; Chong Jim KIM ; Donghoon CHOI ; Yang Soo JANG ; Junghan YOON ; Wook Sung CHUNG ; Jeong Gwan CHO ; Ki Bae SEUNG ; Seung Jung PARK
Korean Circulation Journal 2009;39(6):243-250
BACKGROUND AND OBJECTIVES: It is thought that patients with diabetes mellitus (DM) have a poor prognosis after an acute myocardial infarction (AMI), but the effect of diabetes on the outcomes of hypertensive patients with AMIs has not been elucidated in the Korean population. The aim of this study was to investigate the effects of diabetes on long-term clinical outcomes following AMIs in patients with hypertension. SUBJECTS AND METHODS: Using data from the Korea Acute Myocardial Infarction Registry (November 2005 to December 2006), 2,233 hypertensive patients with AMIs were grouped as follows based on the presence of DM: group I, diabetic hypertension (n=892, 544 men, mean age=66.2+/-10.9 years); and group II, non-diabetic hypertension (n=1341, 938 men, mean age=63.9+/-12.8 years). The primary study outcomes included in-hospital death and major adverse cardiac events (MACE; cardiac death, myocardial infarction (MI), repeat percutaneous coronary intervention, and coronary artery bypass surgery) at the 1 year follow-up. RESULTS: Hypertensive patients with DM were older and more likely to be women. The diabetic group had lower blood pressure (p<0.001), a lower left ventricular ejection fraction (p<0.001), a more severe degree of heart failure (p<0.001), a longer duration of coronary care unit admission (p<0.001), and a higher incidence of hyperlipidemia (p=0.007). The N-terminal pro-brain natriuretic peptide level (4602.5+/-8710.6 pg/mL vs. 2320.8+/-5837.9 pg/mL, p<0.001) was higher and the creatinine clearance (62.4+/-29.9 mL/min vs. 73.0+/-40.8 mL/min, p<0.001) was lower in the diabetic group than the non-diabetic group. Coronary angiographic findings revealed more frequent involvement of the left main stem (p=0.002) and multiple vessels (p<0.001) in the diabetic group. The rate of in-hospital death was higher in the diabetic group (p<0.001). During follow-up, the rates of composite MACE at 1 month, 6 months, and 12 months were higher in the diabetic group (p<0.001). CONCLUSION: In hypertensive patients with AMI, DM was associated with worse clinical and angiographic features, with a higher risk of development of severe heart failure, and an increased risk of MACE on long-term clinical follow-up.
Blood Pressure
;
Coronary Artery Bypass
;
Coronary Care Units
;
Creatinine
;
Death
;
Diabetes Mellitus
;
Female
;
Follow-Up Studies
;
Heart Failure
;
Humans
;
Hyperlipidemias
;
Hypertension
;
Incidence
;
Korea
;
Male
;
Myocardial Infarction
;
Percutaneous Coronary Intervention
;
Prognosis
;
Stroke Volume
7.Regulation of Urea Transporters by Tonicity-responsive Enhancer Binding Protein.
Ju Young JUNG ; Moo KWON ; Jim KIM
Electrolytes & Blood Pressure 2007;5(1):28-33
Urea accumulation in the renal inner medulla plays a key role in the maintenance of maximal urinary concentrating ability. Urea transport in the kidney is mediated by transporter proteins that include renal urea transporter (UT-A) and erythrocyte urea transporter (UT-B). UT-A1 and UT-A2 are produced from the same gene. There is an active tonicity-responsive enhancer (TonE) in the promoter of UT-A1, and the UT-A1 promoter is stimulated by hypertonicity via tonicity-responsive enhancer binding protein (TonEBP). The downregulation of UT-A2 raises the possibility that TonEBP also regulates its promoter. There is some evidence that TonEBP regulates expression of UT-A in vivo; (1) during the renal development of the urinary concentrating ability, expression of TonEBP precedes that of UT-A1; (2) in transgenic mice expressing a dominant negative form of TonEBP, expression of UT-A1 and UT-A2 is severely impaired; (3) in treatment with cyclosporine A, TonEBP was significantly downregulated after 28 days. This downregulation involves mRNA levels of UT-A2; (4) in hypokalemic animals, downregulation of TonEBP contributed to the down regulation of UT-A in the inner medulla. These data support that TonEBP directly contributes to the urinary concentration and renal urea recycling by the regulation of urea transporters.
Animals
;
Carrier Proteins*
;
Cyclosporine
;
Down-Regulation
;
Erythrocytes
;
Kidney
;
Mice
;
Mice, Transgenic
;
Recycling
;
RNA, Messenger
;
Urea*
8.The Role of the UBC Test in Transitional Cell Carcinomas of the Bladder.
Sang Hyeon CHEON ; Jun Hyuk HONG ; Jim Bum KIM ; Jin Sook RYU ; Han Kwon KIM ; Choung Soo KIM
Korean Journal of Urology 2003;44(1):17-21
PURPOSE: We evaluated the diagnostic performance of a noninvasive bladder cancer test, the urinary bladder cancer (UBC) antigen test, on voided urine samples from patients with active transitional cell carcinomas, on follow-up and controls. MATERIALS AND METHODS: We measured the UBC antigen in the urine from 136 patients with active transitional cell carcinomas of the bladder (group 1), 56 patients with no evidence of tumor recurrence, confirmed by cystoscopy at follow-up (group 2), 60 patients with urinary tract infections (group 3), 52 patients with other genitourinary tract malignancies (group 4) and 74 healthy subjects, free from urological diseases (group 5). RESULTS: The mean UBC antigen concentrations were 75.79, 28.95, 52.90, 16.90 and 7.56micro gram/L, in groups 1 to 5, respectively. Group 2, 4 and 5 showed statistically significant differences in the UBC concentrations compared to group 1 (p=0.03, <0.001 and <0.001, respectively). Sensitivity and specificity were 61.8 and 68.2%, at a threshold value of 9.7micro gram/L, from group 1, compared to groups 2 to 5. As for the tumor grade in group 1, there were significant differences between grade I and II (p<0.001) or between grade I and III (p<0.001), but there were no significant differences according to the T stage. CONCLUSIONS: The UBC test might have a role as a potential tumor marker for the diagnosis of transitional cell carcinomas of the bladder adjunct to cystoscopy.
Carcinoma, Transitional Cell*
;
Cystoscopy
;
Diagnosis
;
Follow-Up Studies
;
Humans
;
Keratins
;
Recurrence
;
Sensitivity and Specificity
;
Biomarkers, Tumor
;
Urinary Bladder Neoplasms
;
Urinary Bladder*
;
Urinary Tract Infections
;
Urologic Diseases
9.The Role of the UBC Test in Transitional Cell Carcinomas of the Bladder.
Sang Hyeon CHEON ; Jun Hyuk HONG ; Jim Bum KIM ; Jin Sook RYU ; Han Kwon KIM ; Choung Soo KIM
Korean Journal of Urology 2003;44(1):17-21
PURPOSE: We evaluated the diagnostic performance of a noninvasive bladder cancer test, the urinary bladder cancer (UBC) antigen test, on voided urine samples from patients with active transitional cell carcinomas, on follow-up and controls. MATERIALS AND METHODS: We measured the UBC antigen in the urine from 136 patients with active transitional cell carcinomas of the bladder (group 1), 56 patients with no evidence of tumor recurrence, confirmed by cystoscopy at follow-up (group 2), 60 patients with urinary tract infections (group 3), 52 patients with other genitourinary tract malignancies (group 4) and 74 healthy subjects, free from urological diseases (group 5). RESULTS: The mean UBC antigen concentrations were 75.79, 28.95, 52.90, 16.90 and 7.56micro gram/L, in groups 1 to 5, respectively. Group 2, 4 and 5 showed statistically significant differences in the UBC concentrations compared to group 1 (p=0.03, <0.001 and <0.001, respectively). Sensitivity and specificity were 61.8 and 68.2%, at a threshold value of 9.7micro gram/L, from group 1, compared to groups 2 to 5. As for the tumor grade in group 1, there were significant differences between grade I and II (p<0.001) or between grade I and III (p<0.001), but there were no significant differences according to the T stage. CONCLUSIONS: The UBC test might have a role as a potential tumor marker for the diagnosis of transitional cell carcinomas of the bladder adjunct to cystoscopy.
Carcinoma, Transitional Cell*
;
Cystoscopy
;
Diagnosis
;
Follow-Up Studies
;
Humans
;
Keratins
;
Recurrence
;
Sensitivity and Specificity
;
Biomarkers, Tumor
;
Urinary Bladder Neoplasms
;
Urinary Bladder*
;
Urinary Tract Infections
;
Urologic Diseases
10.Silicone Tube Frontalis Sling For the Correction of Blepharoptosis.
Sang Duck KIM ; Pil Sung KANG ; Jim Han PAE ; Jae Duck KIM
Journal of the Korean Ophthalmological Society 2000;41(12):2521-2526
No Abstract Available.
Blepharoptosis*
;
Silicones*

Result Analysis
Print
Save
E-mail